NovoCure Limited (NASDAQ: NVCR) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT NOVOCURE LIMITED

NovoCure Limited (NASDAQ: NVCR)
Listen to this Section


$17.87
+1.7150 ( +10.62% ) 1.2M

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Market Data


Open $17.87
Previous Close $16.15
Volume 1.2M
Market Cap $1.87B
Day Range $14.99 - $18.38
52 Week Range $9.82 - $19.25
Shares Outstanding 115.82M
Change % +10.62%
Net Change ▲ 1.7150
Insider Ownership 0.00%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2015
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 82,880.00

Date Type Amount Purchased Purchaser
2025-09-08 Buy 81550.00 Cordova Ashley
2025-07-30 Buy 10000.00 Brackmann Christoph
2024-08-06 Sale -1736.00 Puri Michal Nath
2024-08-06 Sale -1736.00 Leonard Frank X
2024-08-06 Sale -1286.00 Cordova Ashley
2024-08-06 Sale -1239.00 Danziger Asaf
2024-08-06 Sale -1055.00 GROENHUYSEN WILHELMUS CM
2024-08-06 Sale -930.00 Ben Arye Barak
2024-08-05 Sale -688.00 Cordova Ashley

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 04, 2025
4 Insider transactions 1 Nov 04, 2025
4 Insider transactions 1 Nov 04, 2025
4 Insider transactions 1 Nov 04, 2025
10-q Quarterly Reports 65 Oct 30, 2025
8-k 8K-related 13 Oct 30, 2025
8-k 8K-related 13 Sep 15, 2025
4 Insider transactions 1 Sep 08, 2025
8-k 8K-related 12 Aug 28, 2025
4 Insider transactions 1 Jul 30, 2025

Latest News


× Before browsing our site, please accept our cookies policy